Nontoxic mucosal adjuvant

Details Nontoxic mucosal adjuvant Nontoxic mucosal adjuvant

2006-07-04

2006-07-04

Minnifield, N. M. (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S265100, C424S234100, C424S245100, C424S254100, C424S832000, C424S236100, C424S204100, C424S206100, C424S217100, C424S261100, C424S257100, C424S278100, C424S282100, C424S231100, C424S250100, C424S249100, C424S240100, C514S002600, C514S012200

Reexamination Certificate

active

07070781

ABSTRACT:
A non-toxic mucosal adjuvant is provided which may be admixed with further antigens to provide a vaccine administrable to mucosal surfaces in organisms including man. Preferably, the non-toxic mucosal adjuvant is a detoxified mutant of a bacterial ADP-ribosylating toxin, optionally comprising one or more amino acid additions, deletions or substitutions.

REFERENCES:
patent: 4328209 (1982-05-01), Finkelstein et al.
patent: 4428931 (1984-01-01), Tolman et al.
patent: 4666837 (1987-05-01), Harford et al.
patent: 4892827 (1990-01-01), Pastan et al.
patent: 4925792 (1990-05-01), Rappuoli
patent: 5032398 (1991-07-01), Kaslow
patent: 5085862 (1992-02-01), Klein et al.
patent: 5182109 (1993-01-01), Tamura et al.
patent: 5221618 (1993-06-01), Klein et al.
patent: 5241053 (1993-08-01), Fujisawa et al.
patent: 5244657 (1993-09-01), Klein et al.
patent: 5332583 (1994-07-01), Klein et al.
patent: 5358868 (1994-10-01), Klein et al.
patent: 5427788 (1995-06-01), Rappuoli et al.
patent: 5433945 (1995-07-01), Klein et al.
patent: 5668255 (1997-09-01), Murphy
patent: 5747028 (1998-05-01), Calderwood et al.
patent: 5770203 (1998-06-01), Burnette et al.
patent: 5773600 (1998-06-01), Burnette, III
patent: 5785971 (1998-07-01), Rappuoli et al.
patent: 5786189 (1998-07-01), Locht et al.
patent: 5856122 (1999-01-01), Read et al.
patent: 5874088 (1999-02-01), Mekalanos
patent: 5874287 (1999-02-01), Burnette et al.
patent: 5882653 (1999-03-01), Kaper et al.
patent: 5889172 (1999-03-01), Pizza et al.
patent: 5908825 (1999-06-01), Fasano et al.
patent: 5925546 (1999-07-01), Pizza et al.
patent: 5942418 (1999-08-01), Loosmore et al.
patent: 5961970 (1999-10-01), Lowell et al.
patent: 5965385 (1999-10-01), Read et al.
patent: 5977304 (1999-11-01), Read et al.
patent: 5985284 (1999-11-01), Lowell
patent: 6019982 (2000-02-01), Clements
patent: 6030624 (2000-02-01), Russell et al.
patent: 6033673 (2000-03-01), Clements
patent: 6129923 (2000-10-01), Doidge et al.
patent: 6149919 (2000-11-01), Domenighini et al.
patent: 6350612 (2002-02-01), Rappuoli et al.
patent: 6436407 (2002-08-01), Clements et al.
patent: 6440423 (2002-08-01), Clements et al.
patent: 6818222 (2004-11-01), Barchfeld et al.
patent: 6841155 (2005-01-01), Del Giudice et al.
patent: 6855321 (2005-02-01), Rappuoli et al.
patent: 2001/0018056 (2001-08-01), Roberts
patent: 2002/0044939 (2002-04-01), Pizza et al.
patent: 2002/0187154 (2002-12-01), Rappuoli
patent: 2003/0072764 (2003-04-01), O'Hagan
patent: 2003/0113338 (2003-06-01), Pizza et al.
patent: 2003/0170262 (2003-09-01), Pizza et al.
patent: 2003/0176653 (2003-09-01), Mason et al.
patent: 2004/0028690 (2004-02-01), Rappuoli
patent: 2004/0109874 (2004-06-01), Chen et al.
patent: 2005/0106180 (2005-05-01), Barchfeld et al.
patent: 2005/0136076 (2005-06-01), Pizza et al.
patent: 372928 (1990-06-01), None
patent: 0396964 (1990-11-01), None
patent: 0462534 (1991-12-01), None
patent: 0 688 868 (1995-12-01), None
patent: 919243 (1999-06-01), None
patent: WO 92/19265 (1992-11-01), None
patent: WO 93/13202 (1993-08-01), None
patent: WO 95/09649 (1995-04-01), None
patent: WO 95/17211 (1995-06-01), None
patent: WO 95/34323 (1995-12-01), None
patent: WO 96/06627 (1996-03-01), None
patent: WO 97/02045 (1997-01-01), None
patent: WO 99/36088 (1999-07-01), None
patent: WO 99/58145 (1999-11-01), None
patent: WO 00/18434 (2000-04-01), None
patent: WO 00/69456 (2000-11-01), None
patent: WO 02/38177 (2002-02-01), None
Fujihashi et al, Vaccine, 2002, 20:2431-2438.
Kang et al, Protein Expression and Purification, 2004, 38:123-128.
Freytag et al, Vaccine, 2005, 23:1804-1813.
McCluskie et al, Vaccine, 2001, 19:3759-3768.
Takahashi et al, J. Infectious Diseases, 1996, 173:627-635.
Chen, J. Controlled Release, 2000, 67:117-128.
Quere et al, Vet. Immunology and Immunopathology, 70:135-141.
Pizza et al, Vaccine, 2001, 19:2534-2541.
Gu et al, International Congress Series, 2003, 1257:63-67.
Eriksson et al, Current Opinion in Immunology, 2002, 14:666-672.
O'Hagan et al, Biomolecular Engineering, 2001, 18:69-85.
Elson, Current Topics in Microbiology and Immunology, 1989, 146:29-33.
Cheng et al, Vaccine, 2000, 18:38-49.
Foss et al, Vaccine, 1999, 17:788-801.
Baqar et al, Vaccine, 1995, 13/1:22-28.
Scharton-Kersten et al, Vaccine, 1999, 17:S37-S43.
Del Guidice et al, Vaccine, 1999, 17:S44-S52.
Yokomizo et al, Vet. Immunology and Immunopathology, 2002, 87:291-300.
Watanabe et al, Vaccine, 2002, 20:3443-3455.
Lemere et al, Neurobiology of Aging, 2002, 23:991-1000.
Sougioultzis et al, Vaccine, 2002, 21:194-201.
Losonsky et al, Vaccine, 2003, 21:S62-S65.
Periwal et al, Vaccine, 2003, 21:376-385.
Holmgren et al, Vaccine, 2003, 21:S2/89-S2/95.
Baudner et al, Vaccine, 2003, 21:3837-3844.
Nicollier-Jarnot et al, Vaccine, 2004, 22:1079-1086.
Anderson et al., “Immunogens Consisting of Oligosaccharides from the Capsule ofHaemophilus InfluenzaeType b Coupled to Diphtheria Toxoid or the Toxin Protein CRM197,”J. Clin. Invest. 76:52-59 (1985).
Anderson, “Antibody Responses to haemophiles Influenzae Type b and Diptheria Toxin Induced by Conjugates of Oligosaccharides of the Type b Capsule with the Nontoxic Protein CRM197,”Inf.&Immun. 39(1):233-238 (1983).
Bartley et al., “Pertusis Holotoxoid Formed in vitro with a Genetically Deactivated S1 Subunit,”PNAS USA 86:8353-8357 (1989).
Bennett et al., “A Comparison of Commercially Available Adjuvants for Use in Research,”J. Immunol. Methods 153:31-40 (1992).
Black et al., “Construction and Characterization of Bordetella pertussis Toxin Mutants,”Infection&Immunity 55(10):2465-2470 (1987).
Boslego et al., “Gonorrhea Vaccines,”Vaccines and ImmunotherapyChapter 17, pp 211-223 (1991).
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science 247:1306-1310 (1990).
Brandtzaeg, “Overview of the Mucosal Immune System,”Current Topics Microbiol.&Immunol 146:13-25 (1989).
Burnette, “AB5ADP-Ribosylating Toxins: Comparative Anatomy and Physiology,”Structure 2(3):151-158.(1994).
Burnette et al., “Site-specific mutagenesis of the catalytic subunit of cholera toxin: substituting lysine for Arginine 7 causes loss of activity,”Infect.&Immun. 59:4266-4270 (1991).
Carbonetti et al., “Intracellular Delivery of Cytolytic T-Lymphocyte Epitope Peptide by Pertussis Toxin to Major Histocompatibility Complex Class I Without Involvement of the Cytosolic Class I Antigen Processing Pathway,”Infection&Immunity 67(2):602-607 (1999).
Clements et al., “Adjuvant activity ofEscherichia coliheat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens,”Vaccine 6:269-277 (1988).
Czerkinsky, C. et al., “Oral Administration of a Streptococcal Antigen Coupled to Cholera Toxin B Subunit Evokes strong Antibody Responses in Salivary Galnds and Extramucosal Tissues,”Infect.&Immun. 57:1072-1077 (1989).
de Haan et al., “Mucosal Immunogenicity of theEscherichia coliHeat-Labile Enterotoxin: Role of the A Subunit,”Vaccine 14(4):260-266 (1996).
Dertbaugh, M.T. et al., “Reduction in Oral Immunogenicity of Cholera Toxin B Subunit by N-terminal Peptide Addition,”Infect&Immun. 61:384-390 (1993).
Dertzbaugh, M.T. et al., “Comparative Effectiveness of the Cholera Toxin B Subunit and Alkaline Phosphatase as Carriers for Oral Vaccines,”Infect&Immun. 61:48-55 (1993).
Dickinson et al., “Dissociation ofEscherichia coliheat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity,”Infect.&Immun. 63:1617-1623 (1995).
Douce et al., “Genetically Detoxified Mutants of Heat-Labile Toxin fromEscherichia coliAre aBle to Act as Oral Adjuvants,”Infection and Immunity 67(9):4400-4406 (1999).
Douce et al., “Mutants ofEscherichia coliheat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants,”Proc. Natl. Acad. Sci. 92:1644-

Affiliated with

Also associated with

Rating

Nontoxic mucosal adjuvant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nontoxic mucosal adjuvant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nontoxic mucosal adjuvant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3553533